Philippines - English - FDA (Food And Drug Administration)

sanofi pasteur, inc.; distributor: zuellig pharma corporation - quadrivalent seasonal influenza vaccine (split) virion, inactivated) 2024 southern hemisphere strain. - suspension for injection (im) - formulation: each dose (0.5 ml) contains the following influenza strains*: a/sydney/5/2021 (h1n1) pdm09-like virus (a/sydney/5/2021, san-013) 15 μg of ha** a/darwin/9/2021 (h3n2)-like virus (a/darwin/9/2021, ivr-228) 15 μg of ha** b/austria/1359417/2021 (b/victoria lineage)-like virus (b/michigan/01/2021, wild type) 15 μg of ha** b/phuket/3073/2013 (b/yamagata lineage)-like virus (b/phuket/3073/2013, wild type) 15 μg of ha** *propagated in fertilized hen's eggs from healthy chicken flocks **haemagglutinin

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - a/darwin/9/2021 (h3n2)-like virus; a/victoria/4897/2022 (h1n1)pdm09-like virus; b/austria/1359417/2021 (b/victoria lineage)-like virus; b/phuket/3073/2013 (b/yamagata lineage)-like virus - suspension for injection - b/phuket/3073/2013 (b/yamagata lineage)-like virus 30 mcg ha / 1 ml; b/austria/1359417/2021 (b/victoria lineage)-like virus 30 mcg ha / 1 ml; a/darwin/9/2021 (h3n2)-like virus 30 mcg ha / 1 ml; a/victoria/4897/2022 (h1n1)pdm09-like virus 30 mcg ha / 1 ml - influenza, inactivated, split virus or surface antigen - fluarix tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza a virus subtypes and the two influenza b virus types contained in the vaccine.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - influenza virus haemagglutinin -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

hayat medications trading sole proprietorship llc china - 1 pre-filled syringe (0.5 ml) - injection - 0.5 mg/syringe - immunologicals , vaccines-vaccines , antisera

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

g42 medication trading license llc china - 1 glass vial (0.5 ml) - injection - 0.5 ml/vial - immunologicals , vaccines-vaccines , antisera

Kenya - English - Pharmacy and Poisons Board

sanofi pasteur s.a. 2 avenue pont pasteur 69007 lyon - influenza ah1n1 influenza ah3n2 and influenza b - suspension for injection - each 0.5 ml dose contains: influenza ah1n1...15… - viral vaccines: influenza vaccines

Singapore - English - HSA (Health Sciences Authority)

seqirus pte. ltd. - pandemic influenza virus type a, inactivated and disrupted - injection, suspension - pandemic influenza virus type a, inactivated and disrupted 30 mcg ha / 0.5 ml

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) antigen (formaldehyde inactivated) (unii: xw4jb03ti5) (influenza a virus a/brisbane/02/2018 ivr-190 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:92xe6ghc89), influenza a virus a/kansas/14/2017 x-327 (h3n2) antigen (formaldehyde inactivated) (unii: 3nzw5nd3d6) (influenza a virus a/kansas/14/2017 x-327 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:k329ycd1n9), influenza b virus b/maryland/15/2016 bx-69a antigen (formaldeh - influenza a virus a/michigan/45/2015 x-275 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 60 ug in 0.5 ml - fluzone® high-dose is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza a subtype viruses and type b virus contained in the vaccine. fluzone high-dose is approved for use in persons 65 years of age and older. a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine [see description (11) ], including egg protein, or to a previous dose of any influenza vaccine is a contraindication to administration of fluzone high-dose. fluzone high-dose is not approved for use in persons <65 years of age. there are limited human data and no animal data available to establish whether there is a vaccine-associated risk with use of fluzone high-dose in pregnancy. fluzone high-dose is not approved for use in persons <65 years of age. no human or animal data are available to assess the effects of fluzone high-dose on the breastfed infant or on milk production/excretion. safety and effectiveness of fluzone high-dose in persons <65 years of age have not bee

Kenya - English - Pharmacy and Poisons Board

influenza vaccine (surface antigen, inactivated) - injection - influenza virus (surface antigen, inactivated… - influenza inactivated split virus or surface

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a); influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a); influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) - suspension for injection - 9 mcg - active: influenza virus a/california/7/2009 (h1n1) - like strain 9ug (a/california/7/2009 nymc x-179a) influenza virus a/texas/50/2012 (h3n2) like strain 9ug (a/texas/50/2012 nymc x-223a) influenza virus b/massachusetts/2/2012 like strain 9ug (wild type) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection - intanza 9mcg is indicated for prophylaxis of influenza in adults from 18 to 59 years of age. the use of intanza 9mcg in new zealand should be based on the ministry of health recommendations for influenza vaccination as published in the current new zealand immunisation handbook.